Yeah they definitely chose the right path and are going where the money is, very composed company unraveling before our eyes and we get the opportunity to own a share for a penny... We have to be seeing that patent issuance sooner than later, when things like this are put into the limelight they tend to get 'pushed through' per say.
As far as the funding of the cancer portion goes, I think they'll be ready to engage in clinical trials before they have the revenue to fund the trials, it's very expensive. They'll need to license the technology to bigger pharma or partner with them and if all their tests show positive signs I don't foresee that being an issue at all, I'm sure they'll have a plethora of choices.